Skip to main content
Premium Trial:

Request an Annual Quote

Merck to Use Numerate's In Silico Drug Design Platform

Premium

Numerate said this week that Merck will use its in silico drug design platform to generate small-molecule drug leads for an undisclosed cardiovascular disease target.

Financial details of the agreement were not disclosed.

Numerate's CEO Guido Lanza said in statement that the company was "pleased" to add Merck to its client list.

That list includes Boehringer Ingelheim, whose researchers are using the platform to generate drug leads for an unnamed infectious disease target (BI 12/09/11).

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.